Endometrial Cancer

>

Latest News

“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.
Dostarlimab With Chemo Changes Practice for dMMR Endometrial Cancer

August 20th 2024

“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.

Subgroup analysis data from DUO-E support the European approval of durvalumab-based treatment in primary or recurrent endometrial cancer.
Durvalumab Combos Receive EU Approval in pMMR/dMMR Endometrial Cancer

August 14th 2024

Data from the RUBY trial support the expanded approval of dostarlimab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
FDA Expands Approval for Dostarlimab/Chemo in Advanced Endometrial Cancer

August 1st 2024

A statistically significant and clinically meaningful improvement in progression-free survival in the phase 3 trial DUO-E support the recommendation.
Durvalumab Regimens Are Recommended for EU Approval for pMMR, dMMR Endometrial Cancer

July 8th 2024

Tissue biopsy was recommended among Black patients at risk of endometrial cancer over the common ultrasonography triage strategy.
Transvaginal Ultrasounds May Not Detect Endometrial Cancer in Black Women

July 2nd 2024